Published in Arthritis Rheum on November 01, 2010
Etanercept does not impair healing in rat models of tendon or metaphyseal bone injury. Acta Orthop (2012) 1.50
Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation. Clin Exp Immunol (2015) 0.90
Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis. Pharm Res (2011) 0.90
IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis. J Clin Immunol (2012) 0.84
Decreased interleukin-20 level in patients with systemic sclerosis: are they related with angiogenesis? Clin Rheumatol (2013) 0.79
Anti-IL-20 monoclonal antibody inhibited inflammation and protected against cartilage destruction in murine models of osteoarthritis. PLoS One (2017) 0.75
Purification, crystallization and preliminary X-ray diffraction analysis of the IL-20-IL-20R1-IL-20R2 complex. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.75
Inhibition of synovitis and joint destruction by a new single domain antibody specific for cyclophilin A in two different mouse models of rheumatoid arthritis. Arthritis Res Ther (2013) 0.75
Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis. Sci Rep (2016) 0.75
Emerging Therapies for Rheumatoid Arthritis. Rheumatol Ther (2016) 0.75
IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol (2006) 1.73
Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med (2011) 1.62
Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford) (2011) 1.51
Induced interleukin-19 contributes to cell-mediated immunosuppression in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Ann Thorac Surg (2011) 1.50
Induction of interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass. Ann Thorac Surg (2006) 1.47
IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol (2004) 1.39
Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum (2006) 1.31
IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol (2002) 1.20
IL-20: biological functions and clinical implications. J Biomed Sci (2006) 1.11
Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol (2005) 0.98
IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol (2009) 0.94
IL-19 is involved in the pathogenesis of endotoxic shock. Shock (2008) 0.93
Cloning and characterization of mouse IL-22 binding protein. Genes Immun (2003) 0.92
The in vivo biological effects of intradiscal recombinant human bone morphogenetic protein-2 on the injured intervertebral disc: an animal experiment. Spine (Phila Pa 1976) (2007) 0.92
Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol (2005) 0.92
Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome. Clin Cancer Res (2011) 0.91
Expression of IL-19 correlates with Th2 cytokines in uraemic patients. Nephrol Dial Transplant (2007) 0.90
Tissue microarray analysis of interleukin-20 expression. Cytokine (2006) 0.89
Regulatory effects of novel neurotrophin-1/b cell-stimulating factor-3 (cardiotrophin-like cytokine) on B cell function. J Immunol (2002) 0.89
IL-24 inhibits the growth of hepatoma cells in vivo. Genes Immun (2005) 0.89
IL-20 and IL-20R1 antibodies protect against liver fibrosis. Hepatology (2014) 0.89
IL-20 may contribute to the pathogenesis of human intervertebral disc herniation. Spine (Phila Pa 1976) (2008) 0.89
Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol (2008) 0.88
Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol (2012) 0.88
Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol Cancer Res (2012) 0.88
The distribution of interleukin-19 in healthy and neoplastic tissue. Cytokine (2008) 0.87
Interleukin-19 in breast cancer. Clin Dev Immunol (2013) 0.84
Interleukin-20 targets renal cells and is associated with chronic kidney disease. Biochem Biophys Res Commun (2008) 0.83
Interleukin-19 mediates tissue damage in murine ischemic acute kidney injury. PLoS One (2013) 0.82
Interleukin (IL)-19 promoted skin wound healing by increasing fibroblast keratinocyte growth factor expression. Cytokine (2013) 0.80
The therapeutic potential of anti-interleukin-20 monoclonal antibody. Cell Transplant (2014) 0.80
Promoter analysis of interleukin 19. Biochem Biophys Res Commun (2006) 0.77
A methionine-restricted diet and endurance exercise decrease bone mass and extrinsic strength but increase intrinsic strength in growing male rats. J Nutr (2014) 0.76
Inhibiting interleukin-19 activity ameliorates esophageal squamous cell carcinoma progression. PLoS One (2013) 0.75
CSAM: using clustering-hashing-signal anchoring method to explore human novel genes. J Comput Biol (2006) 0.75
Mouse interleukin-20 receptor 1a targets renal epithelial cells and is associated with renal calcium deposition. Genes Immun (2008) 0.75